{"name":"Oxford Nanopore Technologies","slug":"oxford-nanopore","ticker":"ONT.L","exchange":"LSE","domain":"nanoporetech.com","description":"Oxford Nanopore Technologies plc is a UK-based company which develops and sells nanopore sequencing products for the direct, electronic analysis of single molecules. It is listed on the London Stock Exchange and is a constituent of the FTSE 250 Index.","hq":"Oxford, United Kingdom","founded":2014,"employees":"1316","ceo":"Gordon Sanghera","sector":"Genomic Sequencing / Life Sciences Tools","stockPrice":123.6,"stockChange":3.1,"stockChangePercent":2.57,"marketCap":"$1.6B","metrics":{"revenue":300815493.79,"revenueGrowth":19.4,"grossMargin":60.9,"rdSpend":0,"netIncome":-195079989.72,"cash":343002213.33000004,"dividendYield":0,"peRatio":-16.4,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2023-02-28","type":"earnings","headline":"Oxford Nanopore Technologies reports strong revenue growth in Q4 2022","summary":"The company reported revenue of £123.4 million, up 34% year-over-year, driven by strong demand for its sequencing platforms.","drugName":"","sentiment":"positive"},{"date":"2022-09-01","type":"deal","headline":"Oxford Nanopore Technologies partners with Illumina to expand sequencing capabilities","summary":"The partnership aims to integrate Oxford Nanopore's sequencing technology with Illumina's genomics expertise to accelerate genomic research and diagnostics.","drugName":"","sentiment":"neutral"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxQa0tKTXVRakhWZ2JWWW80UGFBdlBjdXlpdEVwMzJUZ0ZpdFBxOFdlbGJMYld4VHoxTV8zYmw0WTZlckdyckFnTkxMZl9hcE1fZGtBaFFwOGhVUldjSUh1OTdrWTZZc3oyT19ZR2pId19oZmxhOWNjRGJEdzU3bDN0Vjl4R0NJRDc5dGhtdDd1TGYxVm5lTzFvVWVR?oc=5","date":"2026-03-11","type":"pipeline","source":"Yahoo Finance","summary":"Oxford Nanopore Technologies Conference: Clinical Sales Surge as Growth Targets Reset, Break-Even Delayed - Yahoo Finance","headline":"Oxford Nanopore Technologies Conference: Clinical Sales Surge as Growth Targets Reset, Break-Even Delayed","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTFBFa21UYWNhYVhjdjVaUk5qUWhZREZKdUZxYzB3NDlfNTZyeGNJWDBNdTFIVjB4bHo1WUl1dXotSTVuZGhWYW44RVFjR0ZwUkJqdVB6RHFndzEzejVoUEVz?oc=5","date":"2026-01-25","type":"pipeline","source":"nature.com","summary":"Amplicon sequencing with Oxford nanopore technologies as a diagnostic alternative for small ruminant lentiviruses in sheep - nature.com","headline":"Amplicon sequencing with Oxford nanopore technologies as a diagnostic alternative for small ruminant lentiviruses in she","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMifkFVX3lxTFBJaDBOQnVpbkpZbUpkU1FsS2Zyd3hZdGN0VTFJbFJ4bFVOLWIzTnE1UENZWUt0VVVOb21fWU9zNmp5c3BPV2FJbGQtQzZTUjFEdHVGRGFidzRSaFdnblFOYll2RmQwUWF2VVFIelZNYV96SnpwMldmR2k4QThXdw?oc=5","date":"2026-01-23","type":"pipeline","source":"Yahoo Finance UK","summary":"$4.5 Billion Whole Genome Sequencing Market Outlook, 2031 Featuring Profiles of Illumina, Thermo Fisher Scientific, Oxford Nanopore Technologies and Other Leading Players - Yahoo Finance UK","headline":"$4.5 Billion Whole Genome Sequencing Market Outlook, 2031 Featuring Profiles of Illumina, Thermo Fisher Scientific, Oxfo","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMif0FVX3lxTE9DU1lJdmE4M29NOFQ0US1fVmVaV1I1QjlEcGRFdUNKb3BtMWhoSGdKUmVLWUVnTXExRHhZb19MT18xV01HSXdLMDRtdnlJRVhITmxNc1UtWFI4REtJVTNNaWhHSThCSWFnT3JtS2NrRTctRWFtekRJZ1FOWXRtRzA?oc=5","date":"2025-01-15","type":"pipeline","source":"Nanalyze","summary":"Oxford Nanopore: The Next Big Genomics Winner? - Nanalyze","headline":"Oxford Nanopore: The Next Big Genomics Winner?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxPcW90ZzFadUdtb0xpdE9wNFhodUVBUVhLOHdOWmQ2VjlVVmhiZHBpNlZYR1l6eE9wZWRJUDRZRUZKRnp1elF1UUI5RURXcUpzZ2lJSVVSMVd5Q1RVYjV2SVl4V0tMaXh2RG5IbWU2elgxSXNfNDdmTmRMb09JbDlRS3dJLTNfVUJXZzktOVIwVFNqSWdx?oc=5","date":"2023-11-12","type":"pipeline","source":"Frontiers","summary":"Targeted haplotyping in pharmacogenomics using Oxford Nanopore Technologies’ adaptive sampling - Frontiers","headline":"Targeted haplotyping in pharmacogenomics using Oxford Nanopore Technologies’ adaptive sampling","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMidkFVX3lxTE1lNzZoZE93UTdVdzJRaklkek1yZ2I2UDhPalZiVnB2QllKMUcyZ2pCMW9IeUo1a2dJbUVPRkZoWU9UMVNmSGczRDh3dTljclZQSWJmSlM5WE9YdzEyTE12MjJFOGVZejZYSWR0aFFHTDZZdTk1OFE?oc=5","date":"2023-03-27","type":"pipeline","source":"Nanalyze","summary":"Checking in With Oxford Nanopore Stock - Nanalyze","headline":"Checking in With Oxford Nanopore Stock","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxOVWhBbWZnWVp0MGFOMDlhR3AzOXhFZThPM2hhend5R0Zxc3ZSXzhuZzRrVnRrenJZMUNUd3pPbmdZUlNhdTdoS0xObTR1UGtqY2N1aENDdURQLWhCQktCOWhkS2ZrZC05VHBKSi1pb2dRMkxnUnJnQjk3Wi1xa29aakNwQmJiQ2I0bWFubHBvWkM5Q2dHQUhqN0ZRZ21RTjBtUW8zNWxB?oc=5","date":"2023-03-23","type":"earnings","source":"CMC Markets","summary":"Oxford Nanopore scores higher revenues and smaller losses in 2022 - CMC Markets","headline":"Oxford Nanopore scores higher revenues and smaller losses in 2022","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMie0FVX3lxTFBpR2cyaUdaUzZiZ2RGQk9ESTRFMHQza0NOSmE2QW9uYlFHeE1WSUdHcFhHbXI1bDlJVkZELUFaYW9xR2dEeHo0Y3luWF9WYkdraEVwRk8yMlZrMXlkTEd0SFJoa1RQR2tiTzNlenRrNi05c19FQUhrSlNubw?oc=5","date":"2022-03-20","type":"pipeline","source":"MarketBeat","summary":"Top Oxford Nanopore Technologies (ONT) Competitors 2026 - MarketBeat","headline":"Top Oxford Nanopore Technologies (ONT) Competitors 2026","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiYkFVX3lxTE1JV253bjFVMGtURUdZYWJ3bDRCRG9fSFVHUGFUWUFucEhfSTZRSm5TQzA3U1dGSTFPbDZjN1ZzM2J5ZWhLSElvUXdjenZYRkxfMEY3alAyUkc3X3pfTlVFcFl3?oc=5","date":"2022-02-07","type":"pipeline","source":"Yahoo Finance UK","summary":"Oxford Nanopore Technologies plc (ONT.L) income statement - Yahoo Finance UK","headline":"Oxford Nanopore Technologies plc (ONT.L) income statement","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiZ0FVX3lxTE1qSGNZeFV6YVYzZVp2Z3lIVWJ3bGU4ZDNVWVNfVEtjdWdCWWJaUzZpVFZtaVFIUHNhN3FXNnplYm9xc2lKeG1scjhtelBUeFBQM3BiTGhERUlzRlR4MVlnR2x0cWtCTzA?oc=5","date":"2021-11-09","type":"pipeline","source":"Yahoo Finance UK","summary":"Oxford Nanopore Technologies plc (ONT.L) valuation measures and financial statistics - Yahoo Finance UK","headline":"Oxford Nanopore Technologies plc (ONT.L) valuation measures and financial statistics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE9MOXN3UWpkWWpjaW95YWZBMGhjLVBiblBIQWdWY1ZWSWZncWRpMW5aUVo4ejFENUthY3c2R01sTEFsUTI2SEFrVjZRZk9OekZ0SllyUXN6WmNUcG9YOGtF?oc=5","date":"2021-11-08","type":"pipeline","source":"nature.com","summary":"Nanopore sequencing technology, bioinformatics and applications - nature.com","headline":"Nanopore sequencing technology, bioinformatics and applications","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxOMkJuNFdsN2NVZ2ZhQlc3YThyeVZGaUxXNnE2NDRCeHZuMHB4SHZSQ2x5em9JVEVjakRTWkZadjdsRFE4dEk2N3M0NjZkT0k5d2RhaDZJM09QcDlKX2x3SUh4bE1sRVhtWWx6eG9uSDJ4a3ZmN1E5Mzl5eWFnQUJtbU5BSlE0dWt5TkhwTHpyakxWZGN5UmJ3U0U5WXQ5UGpYTi1tdA?oc=5","date":"2021-09-30","type":"pipeline","source":"Reuters","summary":"Oxford Nanopore surges 45% in rare London biotech listing - Reuters","headline":"Oxford Nanopore surges 45% in rare London biotech listing","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Illumina","Pacific Biosciences","Thermo Fisher Scientific"],"therapeuticFocus":["Genomic Sequencing","Life Sciences Tools"],"financials":{"source":"yahoo_finance","revenue":300815493.79,"revenuePeriod":"2025-12-31","revenueHistory":[{"period":"2025-12-31","value":300815493.79},{"period":"2024-12-31","value":246133981.52},{"period":"2023-12-31","value":227953386.3348},{"period":"2022-12-31","value":266828314.0383}],"grossProfit":176404976.93,"grossProfitHistory":[{"period":"2025-12-31","value":176404976.93},{"period":"2024-12-31","value":141607650.94},{"period":"2023-12-31","value":121563585.0541},{"period":"2022-12-31","value":166341966.441}],"rdSpend":131262499.97,"rdSpendHistory":[{"period":"2025-12-31","value":131262499.97},{"period":"2024-12-31","value":132874731.29},{"period":"2023-12-31","value":139514437.2762},{"period":"2022-12-31","value":92953196.7546}],"sgaSpend":253792080.29000002,"operatingIncome":-208649603.33,"operatingIncomeHistory":[{"period":"2025-12-31","value":-208649603.33},{"period":"2024-12-31","value":-204619025.03},{"period":"2023-12-31","value":-226530592.1949},{"period":"2022-12-31","value":-132309106.8019}],"netIncome":-195079989.72,"netIncomeHistory":[{"period":"2025-12-31","value":-195079989.72},{"period":"2024-12-31","value":-196423515.82000002},{"period":"2023-12-31","value":-207584187.1327},{"period":"2022-12-31","value":-122294463.25250001}],"eps":-0.151,"epsHistory":[{"period":"2025-12-31","value":-0.151},{"period":"2024-12-31","value":-0.16283},{"period":"2023-12-31","value":-0.19},{"period":"2022-12-31","value":-0.11}],"cash":243312576.71,"cashHistory":[{"period":"2025-12-31","value":243312576.71},{"period":"2024-12-31","value":268033456.95000002},{"period":"2023-12-31","value":296295871.9896},{"period":"2022-12-31","value":479340554.90580004}],"totalAssets":836344997.25,"totalLiabilities":213889355.12,"totalDebt":55756333.150000006,"equity":622455642.13,"operatingCashflow":-94852942.66000001,"operatingCashflowHistory":[{"period":"2025-12-31","value":-94852942.66000001},{"period":"2024-12-31","value":-147653518.39000002},{"period":"2023-12-31","value":-184468820.58220002},{"period":"2022-12-31","value":-85751896.8586}],"capex":-61399142.77,"capexHistory":[{"period":"2025-12-31","value":-61399142.77},{"period":"2024-12-31","value":-65295368.46},{"period":"2023-12-31","value":-36664827.269},{"period":"2022-12-31","value":-37343307.9495}],"freeCashflow":-156252085.43,"dividendsPaid":null,"buybacks":null,"employees":1316,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":123.6,"previousClose":120.5,"fiftyTwoWeekHigh":224.8,"fiftyTwoWeekLow":104,"fiftyTwoWeekRange":"104.0 - 224.8","fiftyDayAverage":116.76,"twoHundredDayAverage":142.13,"beta":0.87,"enterpriseValue":1276751090.123757,"forwardPE":-16.4,"priceToBook":2.58,"priceToSales":5.37,"enterpriseToRevenue":4.24,"enterpriseToEbitda":-8.22,"pegRatio":0,"ebitda":-155311617.16,"ebitdaMargin":-51.6,"freeCashflow":-47896705.465,"operatingCashflow":-94852942.66000001,"totalDebt":55756333.150000006,"debtToEquity":9,"currentRatio":3.56,"returnOnAssets":-12,"returnOnEquity":-27.7,"analystRating":"1.8 - Buy","recommendationKey":"buy","numberOfAnalysts":12,"targetMeanPrice":195,"targetHighPrice":240,"targetLowPrice":140,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":42.1,"institutionHeldPercent":40.3,"sharesOutstanding":972516815,"floatShares":394972415,"sharesShort":0,"shortRatio":0,"shortPercentOfFloat":0,"epsTrailing":-0.15,"epsForward":-0.08,"revenuePerShare":0.23,"bookValue":0.48,"officers":[{"age":43,"name":"Mr. Nicholas Patrick Keher","title":"CFO & Director"},{"age":null,"name":"Mr. Lakmal  Jayasinghe","title":"Chief Scientific Officer"},{"age":null,"name":"Mr. Jordan  Herman","title":"Senior VP & General Counsel"},{"age":null,"name":"Mr. John  Schoellerman","title":"Senior Vice President of Corporate & Business Development"},{"age":null,"name":"Mr. Richard  Compton","title":"Senior Vice President of Sales & Commercial Operations"},{"age":null,"name":"Ms. Sarah  Lapworth","title":"Senior Vice President of Global Human Resources"},{"age":null,"name":"Ms. Zoe  McDougall","title":"Senior VP of Strategic Communications & Corporate Affairs"},{"age":null,"name":"Ms. Kathleen  Barnes","title":"Senior Vice President of Population Health & Precision Medicine"}],"industry":"Biotechnology","irWebsite":"","website":"https://nanoporetech.com","phone":"44 80 8502 3445"}}